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Abstract 
Nicotinic acid (NA) can improve vascular function and regeneration independent of 
correcting dyslipidemia. NA, as a potential biosynthetic precursor for NAD+, may elicit these 
vascular benefits through SIRT-mediated NAD+-dependent responses. We hypothesized that 
NA improves endothelial cell function under lipotoxic conditions through NAD+-dependent 
pathways. Angiogenic function in excess palmitate was assessed by tube formation assay 
following treatment of human microvascular endothelial cells (HMVEC) with NA or 
nicotinamide mononucleotide (NMN; a direct NAD+ precursor). Both NA and NMN 
improved HMVEC angiogenic function during palmitate overload. Only NMN increased 
cellular NAD+ and SIRT1 activity, while both compounds activated SIRT2/3. By microarray, 
NA did not induce expression of known SIRT-regulated genes.  However, we found that 
HMVEC robustly express NA receptor GRP109A, whose specific activation recapitulated 
NA-induced improvements in angiogenic function. We conclude that NA improves in vitro 
HMVEC angiogenic function under lipotoxic conditions, perhaps through GPR109A, but 
likely unrelated to NAD+ biosynthesis and SIRT activation. 
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Chapter 1  
1 Introduction 
1.1 Vascular Disease during Obesity and Metabolic 
Syndrome 
The prevalence of obesity and its complications is increasing globally at an alarming rate. 
According to 2008 estimates by the World Health Organization, over 10% of adults 
worldwide are obese, and the rates of childhood obesity are also increasing dramatically 
(World Health Organization, 2013). Although obesity was once associated with 
affluence, it is now increasing in low- and middle-income countries as well (World 
Health Organization, 2013). The increase in obesity over the last half-century can be 
attributed to a gastronomic revolution in the Western world promoting the consumption 
of large portions of food with high fat and sugar content, combined with an increasingly 
sedentary lifestyle (Unger and Scherer, 2010). 
Obesity is defined as the accumulation of abnormal or excessive adipose tissue which 
may cause impairments to health, and which develops due to an energy imbalance in 
calories consumed versus calories expended (World Health Organization, 2013). 
Quantitatively, a body mass index (BMI= weight [kg] / height2 [m2]) of >30 kg/m2 is 
considered obese, although waist/ hip ratio is also used as a measure of abdominal 
obesity. Abdominal obesity is a risk factor for the development of metabolic syndrome. 
The current unified criteria for metabolic syndrome take into account definitions from 
several international organizations (Alberti et al., 2009). These criteria are abdominal 
obesity (increased waist circumference) plus two of the following characteristics: 
elevated plasma triglycerides (≥1.7 mmol/L), elevated fasting blood glucose (≥5.6 
mmol/L), decreased high-density lipoprotein (HDL) cholesterol (<1.03 mmol/L), and 
elevated blood pressure (≥130/85) (Alberti et al., 2009). 
Adipocytes are specialized cells which have evolved to store lipid as an energy source for 
use by non-adipocytes during starvation. Under normal physiological conditions, diet-
derived plasma lipids are taken up by adipocytes and stored as triglycerides (TG), and are 
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later released by lipolysis for use by tissues during fasting (Unger and Scherer, 2010). In 
response to increased lipid availability, adipose tissue undergoes adipogenesis and 
adipocyte hypertrophy to maximize lipid storage capacity (Bays et al., 2008). Coincident 
with adipose expansion is the increased secretion of leptin by adipocytes, which is 
proportional to adipose mass and targets the hypothalamus to reduce food intake (Mattu 
and Randeva, 2013). Leptin also acts to reduce non-adipocyte lipid accumulation by 
activating fatty acid β-oxidation pathways (Unger and Scherer, 2010). However, the 
capacity of adipose tissue to expand in response to fatty acid uptake is limited.  
Under conditions of caloric surplus, once the capacity of the adipose tissue to store 
excess lipid has been exceeded, adipocytes become dysfunctional and uncontrolled TG 
lipolysis ensues, releasing non-esterified fatty acids (NEFAs) into the bloodstream. The 
resulting chronic hyperlipidemia generates insulin resistance in the liver, restricting the 
ability of insulin to regulate hepatic production of very low density lipoproteins 
(VLDL)(Sparks et al., 2012). As a result, VLDL production and flux from the liver 
increases. Increased plasma concentrations of NEFAs and VLDL induce ectopic 
accumulation in tissues not metabolically programmed to store large amounts of excess 
lipid, including the pancreas, skeletal muscle, cardiac tissue, and the vasculature, causing 
tissue damage and generating a low-grade inflammatory state (Nikolopoulou and 
Kadoglou, 2012; Odegaard and Chawla, 2013). The development of metabolic syndrome 
is summarized in Figure 1.1.  
Unfortunately, obesity and metabolic syndrome greatly increase the risk of premature 
mortality, as well as a broad range of chronic co-morbidities, representing a large-scale 
public health crisis. Obesity has been linked to an increased risk of many types of cancer 
(Vucenik and Stains, 2012), type 2 diabetes mellitus (T2DM) (Shao et al., 2013), liver 
disease (Masuoka and Chalasani, 2013), osteoarthritis (Zhuo et al., 2012), and 
reproductive issues (Lim et al., 2013; O'Reilly and Reynolds, 2013). However, some of 
the most widespread consequences of obesity are seen in its detriment to the vasculature. 
Vascular complications due to hyperlipidemia present in multiple vascular beds. 
Atherosclerotic plaque formation occurs in large- to medium-sized arteries (Talayero and 
Sacks, 2011). Plaques can occlude arteries, increasing blood pressure, and are also in  
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Figure 1.1. Organs affected during obesity and metabolic syndrome. 
In the setting of caloric surplus coupled with a sedentary lifestyle, elevated circulating 
fatty acid levels eventually exceed the storage capacity of adipose tissue, resulting in the 
uncontrolled flux of non-esterified fatty acids (NEFAs) into the bloodstream and the 
development of a chronic hyperlipidemic state. Hyperlipidemia causes hepatic insulin 
resistance, which increases hepatic production and flux of very low density lipoprotein 
(VLDL) into the circulation. Increased plasma concentrations of NEFAs and VLDL 
result in ectopic lipid accumulation (yellow circles) in the pancreas, skeletal muscle, 
cardiac tissue, and the vasculature, causing tissue dysfunction. Adapted from Muoio and 
Newgard (2006). 
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danger of rupture, which can generate thromboemboli capable of causing a myocardial 
infarction (Manduteanu and Simionescu, 2012). Hyperlipidemia can also cause peripheral 
artery disease (PAD), a condition involving restricted blood flow to peripheral tissues and 
extremities. In 1-2% of cases, PAD progresses to critical limb ischemia, requiring 
amputation of the affected limb (Teodorescu et al., 2013). Similarly, hyperlipidemia is 
also a strong risk factor for chronic kidney disease. Especially with co-morbid 
hypertension and poor glycemic control, obesity has been linked to nephropathy due to 
glomerular dysfunction, which can progress to end-stage kidney disease and renal failure 
(Maric and Hall, 2011). Given the serious morbidity and mortality associated with 
vascular disease in obesity, therapeutic interventions to attenuate vascular damage 
warrant further study.    
1.2 Endothelial Damage during Metabolic Disease 
Endothelial cells (EC) serve many important physiological functions. Through balancing 
the production and secretion of vasodilators and vasoconstrictors, EC regulate vascular 
tone, ensuring appropriate perfusion of associated tissues. EC also regulate blood fluidity, 
secreting factors to decrease blood viscosity, or to initiate platelet aggregation and 
clotting following injury. The inflammatory process can also be modulated by EC 
through the production of cytokines and adhesion molecules to allow for homing and 
recruitment of immune cells (Widlansky et al., 2003). Furthermore, EC are responsible 
for regeneration and repair of vascular tissue following injury, as well as the maintenance 
of vascularization through angiogenesis. Considering these vital roles, EC dysfunction 
can be detrimental to surrounding tissues. 
EC dysfunction is defined as a broad change in EC phenotype that may contribute the 
clinical development or expression of vascular disease (Levine et al., 1995). In particular, 
this condition is characterized by a decreased availability of the EC-produced vasodilator 
nitric oxide (NO), and increased activity of proatherogenic and vasoconstrictor factors 
(Campia et al., 2012). Endothelial dysfunction was first reported in association with 
obesity by Steinberg et al. (1996), as measured by blunted vasodilation in the legs of 
obese patients in response to infusion of a vasodilator. Endothelial dysfunction has since 
been established as a precursor to vascular disease, and a key process in the development 
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of vascular aspects of metabolic syndrome. In keeping with this, Bigornia et al. (2010) 
showed that endothelial function, measured as flow-mediated dilation of the brachial 
artery, was improved in obese patients who lost weight. EC functional improvement, 
however, was independent of weight loss and most strongly correlated with serum 
glucose levels, suggesting that EC dysfunction is mediated by metabolic abnormalities 
associated with obesity, and not directly with obesity itself. Conversely, the maintenance 
of proper endothelial function potently opposes the development of the atherosclerotic 
and thrombotic phenotypes associated with metabolic syndrome (Xu and Zou, 2009). 
The development of EC dysfunction is a gradual process. When exposed to an insult, 
such as hyperlipidemia or hyperglycemia, EC will first modify their constitutive 
functions in an attempt to adapt to the altered microenvironment. If the insult persists, EC 
will undergo dysfunction, which will eventually lead to injury and cell apoptosis 
(Simionescu, 2007). Initial EC modifications in response to hyperlipidemia include 
increased trafficking of low density lipoprotein (LDL) and VLDL through the 
endothelium as a result of increased circulating cholesterol concentrations, and 
conversion of EC to a secretory phenotype. The shift to a secretory phenotype is 
accompanied by increased secretion of chemotactic factors and alterations in expression 
of adhesion molecules, resulting in monocyte recruitment and the development of a 
chronic inflammatory state (Simionescu, 2007).  
Endothelial cells throughout the body are heterogeneous, resulting in different 
pathological responses to a given stimulus based on blood vessel type and associated 
tissue (Simionescu et al., 1975; Simionescu et al., 1976). In response to chronic 
hyperlipidemia, larger arteries develop atherosclerosis. Atherosclerotic plaques develop 
in the intima of vessel walls, initiated by endothelial functional changes. Plaques expand 
and become fibrotic through the accumulation of LDL cholesterol and the activities of 
infiltrating immune and smooth muscle cells. Plaques can eventually become unstable, 
leading to rupture and thrombotic vascular occlusion resulting in myocardial infarction or 
stroke (Manduteanu and Simionescu, 2012). Despite uniform exposure of the vascular 
tree to circulating insults, atherosclerotic plaques preferentially develop at sites 
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experiencing disturbed flow or altered shear stress, including vessel branch points, 
bifurcations and curvatures (VanderLaan et al., 2004).  
The presentation of microvascular dysfunction in patients with PAD was identified 
several decades ago by Matsen et al. (1980), who observed decreased transcutaneous 
oxygen tension in patients’ extremities. EC dysfunction in microvessels likely develops 
through mechanisms similar to those that occur in large vessel EC, but results in impaired 
blood flow and vasoreactivity rather than atherosclerotic plaque formation (Abularrage et 
al., 2005). Notably, EC dysfunction in the microvasculature is evident long before 
atherosclerotic symptoms develop, serving as an early marker of vascular disease (Verma 
et al., 2003). If left untreated, microvascular dysfunction can progress to critical limb 
ischemia and lead to the necessity for limb amputation. 
1.3 Lipotoxicity in Endothelial Cells 
Lipotoxicity is the process by which excess fatty acids  and their metabolites influence 
membrane structure, intracellular signaling, and energy homeostasis within the cell, 
leading to cell dysfunction and death (Brookheart et al., 2009). In the setting of obesity 
and metabolic syndrome, endothelial cells are especially vulnerable to lipotoxicity 
because they are continuously and directly exposed to high concentrations of fatty acids. 
Moreover, studies in human umbilical vein EC (HUVEC) have indicated that EC 
predominantly generate ATP by aerobic glycolysis, and are therefore inefficient at 
metabolizing fatty acids through β-oxidation or esterification into triglycerides (TG) 
(Dagher et al., 1999; Dagher et al., 2001; Helies-Toussaint et al., 2006). This inability of 
EC to process large quantities of lipid through oxidative or TG storage pathways results 
in the channeling of excess lipid toward pathways that lead to metabolic stress and cell 
dysfunction. Pathways contributing to lipotoxicity in EC are summarized in Figure 1.2, 
and are discussed in detail below. 
It is well established that unsaturated fatty acids, but not saturated fatty acids, are well 
tolerated by cells, and may even protect against damage induced by saturated fatty acids. 
In human EC, and several other cell types, saturated fatty acids such as palmitate induce 
apoptosis, whereas unsaturated fatty acids do not (Ciapaite et al., 2007; Staiger et al., 
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2006).  These results have been recapitulated in vivo, where animals fed a high saturated 
fat, Western-style diet develop symptoms of metabolic disorder, including atherosclerosis 
and peripheral vascular disease (Breslow, 1996; Nishina et al., 1990; Schreyer et al., 
1998; Wang et al., 2009). Clinically, intake of saturated fatty acids increases plasma LDL 
and decreases HDL cholesterol concentrations, resulting in a proatherogenic environment 
(Kris-Etherton and Yu, 1997). By contrast, monounsaturated or polyunsaturated fatty 
acids, such as those found in plant and fish oils, are either neutral or antiatherogenic 
(Carrero and Grimble, 2006; Vecka et al., 2012). 
Saturated FA can lead to ceramide production in the mitochondria via the actions of 
serine palmitoyltransferase and ceramide synthase. Ceramides are intracellular lipid 
second messengers involved in initiating apoptosis in response to injurious stimuli 
(Claria, 2006). Treatment of HUVEC with palmitate has been shown to cause de novo 
synthesis of ceramide and inhibit endothelial nitric oxide synthase (eNOS), reducing NO 
production by EC and generating a dysfunctional phenotype (Xiao-Yun et al., 2009). 
Mugabo et al. (2011) provided further evidence for the role of ceramide in palmitate 
toxicity, as treatment of human aortic EC (HAEC) with ceramide mimicked the 
intracellular signaling events elicited by treatment with palmitate, including decreased 
AMPK activation, and increased protein kinase C (PKC) and NADPH activation, leading 
to reactive oxygen species (ROS) production upstream of eNOS inhibition. Similarly, 
ceramide has been shown to impair microvascular EC function. Treatment of human 
microvascular EC (HMVEC) with ceramide analogues decreased cell proliferation and 
migration and induced apoptosis, while ceramide-treated mice showed reduced tumour 
angiogenesis (Bocci et al., 2012). Therefore, ceramide synthesis from palmitate may be 
one mechanism that contributes to EC dysfunction during lipid overload. 
Based on in vivo data, a key mechanism in the development of EC lipotoxicity appears to 
be increased ROS production (Chinen et al., 2007).  However, ceramide synthesis does 
not appear to be the only pathway that elicits oxidative stress during palmitate overload 
(Listenberger et al., 2001). PKC-dependent ROS generation in EC can also be elicited by 
palmitate induced diacylglycerol production (Inoguchi et al., 2000). Moreover, data from 
rat cardiomyocytes suggests that palmitate is incorporated into phospholipids in the inner  
